bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1-7 from Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma
Authors: Shi Ruoshi , Li Ming , Raghavan Vibha , Tam Shirley , Cabanero Michael , Pham Nhu-An , Shepherd Frances A. , Moghal Nadeem , Tsao Ming-Sound
Published: April 2023

Supplementary Figure S1-7
Figure S1 from Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy
Authors: Hertz Daniel L. , Kidwell Kelley M. , Vangipuram Kiran , Li Feng , Pai Manjunath P. , Burness Monika , Griggs Jennifer J. , Schott Anne F. , Van Poznak Catherine , Hayes Daniel F. , Lavoie Smith Ellen M. , Henry N. Lynn
Published: April 2023

Supplementary Figure 1: Consort Diagram. Of the sixty-five patients enrolled on the prospective observational clinical trial (UMCC2014.002), 60 were eligible for analysis. Analyses of each exposure metric used a subset of these patients due to missed sample collection or assay failure. Abbreviations; D/C: discontinued paclitaxel
Table S1 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Authors: Odegaard Justin I. , Vincent John J. , Mortimer Stefanie , Vowles James V. , Ulrich Bryan C. , Banks Kimberly C. , Fairclough Stephen R. , Zill Oliver A. , Sikora Marcin , Mokhtari Reza , Abdueva Diana , Nagy Rebecca J. , Lee Christine E. , Kiedrowski Lesli A. , Paweletz Cloud P. , Eltoukhy Helmy , Lanman Richard B. , Chudova Darya I. , Talasaz AmirAli
Published: April 2023

Digital Sequencing analytical performance metrics summary table.
Figure S3 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Authors: Odegaard Justin I. , Vincent John J. , Mortimer Stefanie , Vowles James V. , Ulrich Bryan C. , Banks Kimberly C. , Fairclough Stephen R. , Zill Oliver A. , Sikora Marcin , Mokhtari Reza , Abdueva Diana , Nagy Rebecca J. , Lee Christine E. , Kiedrowski Lesli A. , Paweletz Cloud P. , Eltoukhy Helmy , Lanman Richard B. , Chudova Darya I. , Talasaz AmirAli
Published: April 2023

Quantitative accuracy of Digital Sequencing. Quantitative correlation between expected and observed VAFs for SNVs (a) and CNAs (b) in the analytical validation studies. (c) DS copy number calls compared to those reported in the Cancer Cell Line Encyclopedia (CCLE).
Figure S2 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Authors: Odegaard Justin I. , Vincent John J. , Mortimer Stefanie , Vowles James V. , Ulrich Bryan C. , Banks Kimberly C. , Fairclough Stephen R. , Zill Oliver A. , Sikora Marcin , Mokhtari Reza , Abdueva Diana , Nagy Rebecca J. , Lee Christine E. , Kiedrowski Lesli A. , Paweletz Cloud P. , Eltoukhy Helmy , Lanman Richard B. , Chudova Darya I. , Talasaz AmirAli
Published: April 2023

Empirical determination of the limit of detection. Defined oncogenic driver and background SNVs (a), oncogene and tumor suppressor indels (b), and oncogenic fusions (c) were titrated to specified VAFs, and multiple replicates were measured to determine the 95% LOD. (d) Cell lines comprising defined gene amplifications were titrated to bracket the expected LOD, and the 95% LOD was determined from statistical detection models as per the CLSI Classical Approach.
Figure S1 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Authors: Odegaard Justin I. , Vincent John J. , Mortimer Stefanie , Vowles James V. , Ulrich Bryan C. , Banks Kimberly C. , Fairclough Stephen R. , Zill Oliver A. , Sikora Marcin , Mokhtari Reza , Abdueva Diana , Nagy Rebecca J. , Lee Christine E. , Kiedrowski Lesli A. , Paweletz Cloud P. , Eltoukhy Helmy , Lanman Richard B. , Chudova Darya I. , Talasaz AmirAli
Published: April 2023

Genes on the Guardant360 panel.
Figure S6 from Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Authors: L'Italien Lawrence , Orozco Olivia , Abrams Tinya , Cantagallo Lisa , Connor Anu , Desai Jayesh , Ebersbach Hilmar , Gelderblom Hans , Hoffmaster Keith , Lees Emma , Maacke Heiko , Schleyer Siew , Skegro Darko , Lee-Hoeflich Si Tuen
Published: April 2023

F(ab')2-LMJ729 degranulation assay of hIFNg-treated mast cells
Figure S3 from Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Authors: L'Italien Lawrence , Orozco Olivia , Abrams Tinya , Cantagallo Lisa , Connor Anu , Desai Jayesh , Ebersbach Hilmar , Gelderblom Hans , Hoffmaster Keith , Lees Emma , Maacke Heiko , Schleyer Siew , Skegro Darko , Lee-Hoeflich Si Tuen
Published: April 2023

Additional small molecule inhibition of LMJ729/LOP628-mediated degranulation
Figure S2 from Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Authors: L'Italien Lawrence , Orozco Olivia , Abrams Tinya , Cantagallo Lisa , Connor Anu , Desai Jayesh , Ebersbach Hilmar , Gelderblom Hans , Hoffmaster Keith , Lees Emma , Maacke Heiko , Schleyer Siew , Skegro Darko , Lee-Hoeflich Si Tuen
Published: April 2023

Unconjugated LOP628, LMJ729, activity in mast cell degranulation assays
Figure S1 from Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Authors: L'Italien Lawrence , Orozco Olivia , Abrams Tinya , Cantagallo Lisa , Connor Anu , Desai Jayesh , Ebersbach Hilmar , Gelderblom Hans , Hoffmaster Keith , Lees Emma , Maacke Heiko , Schleyer Siew , Skegro Darko , Lee-Hoeflich Si Tuen
Published: April 2023

Representative FACs staining of in vitro generated mast cells confirming maturation
Table S2 from Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
Authors: Xu MengMeng , Casio Michael , Range Danielle E. , Sosa Julie A. , Counter Christopher M.
Published: April 2023

Days per week (up to 7) mice (1-10) were treated with vehicle, vemurafenib, or TM in the 8-week study.
Table S6 from Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas
Authors: Zhu Haibo , Guo Jing , Shen Yutao , Dong Wei , Gao Hua , Miao Yazhou , Li Chuzhong , Zhang Yazhuo
Published: April 2023

Rawdata of differential expression genes of mRNAs, lncRNAs, miRNAs and circRNAs
Table S1 from Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas
Authors: Zhu Haibo , Guo Jing , Shen Yutao , Dong Wei , Gao Hua , Miao Yazhou , Li Chuzhong , Zhang Yazhuo
Published: April 2023

Clinical information of transcriptive microarrays patients
Supplementary Data from Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma
Authors: Duan Meng , Goswami Shyamal , Shi Jie-Yi , Wu Lin-Jie , Wang Xiao-Ying , Ma Jia-Qiang , Zhang Zhao , Shi Yang , Ma Li-Jie , Zhang Shu , Xi Rui-Bin , Cao Ya , Zhou Jian , Fan Jia , Zhang Xiao-Ming , Gao Qiang
Published: April 2023

Supplementary Figures
Supplementary Data from Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma
Authors: Duan Meng , Goswami Shyamal , Shi Jie-Yi , Wu Lin-Jie , Wang Xiao-Ying , Ma Jia-Qiang , Zhang Zhao , Shi Yang , Ma Li-Jie , Zhang Shu , Xi Rui-Bin , Cao Ya , Zhou Jian , Fan Jia , Zhang Xiao-Ming , Gao Qiang
Published: April 2023

Supplementary Table S3
Supplementary Table S3. from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Comprehensive panels of 287 KEGG pathways associated identified by bioinformatics analysis of TFE3 ChIP-seq peaks in RP-R07 cells.
Supplementary Figure 7 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Animal body weights
Supplementary Fig. 4 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Pie chart for TFE3 binding sites
Supplementary Fig. 3 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Pie chart for TFE3 binding sites
Supplementary Data from Hyperspectral Imaging for Resection Margin Assessment during Cancer Surgery
Authors: Kho Esther , de Boer Lisanne L. , Van de Vijver Koen K. , van Duijnhoven Frederieke , Vrancken Peeters Marie-Jeanne T.F.D. , Sterenborg Henricus J.C.M. , Ruers Theo J.M.
Published: April 2023

Overview of the registration process of the H&E sections to hyperspectral images.
Supplementary Data from Hyperspectral Imaging for Resection Margin Assessment during Cancer Surgery
Authors: Kho Esther , de Boer Lisanne L. , Van de Vijver Koen K. , van Duijnhoven Frederieke , Vrancken Peeters Marie-Jeanne T.F.D. , Sterenborg Henricus J.C.M. , Ruers Theo J.M.
Published: April 2023

Example of spectral variability due to non-flat surface of tissue.
Supplementary Figure S2. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
Authors: Dickler Maura N. , Saura Cristina , Richards Donald A. , Krop Ian E. , Cervantes Andrés , Bedard Philippe L. , Patel Manish R. , Pusztai Lajos , Oliveira Mafalda , Cardenas Alison K. , Cui Na , Wilson Timothy R. , Stout Thomas J. , Wei Michael C. , Hsu Jerry Y. , Baselga José
Published: April 2023

Time on treatment by taselisib dose and duration
Supplementary Table S5. Individual Patient Data Meta-Analysis - Randomized Trials from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Authors: Jen Emily Y. , Ko Chia-Wen , Lee Jee Eun , Del Valle Pedro L. , Aydanian Antonina , Jewell Charles , Norsworthy Kelly J. , Przepiorka Donna , Nie Lei , Liu Jiang , Sheth Christopher M. , Shapiro Marjorie , Farrell Ann T. , Pazdur Richard
Published: April 2023

Supplemental Table 5 describes the 5 randomized trials of GO plus chemotherapy reviewed as part of the safety assessment of GO in combination with chemotherapy.
Supplementary Table S4. ALFA-0701 Search Strategy for Grouped Terms, MedDRA v18.0 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Authors: Jen Emily Y. , Ko Chia-Wen , Lee Jee Eun , Del Valle Pedro L. , Aydanian Antonina , Jewell Charles , Norsworthy Kelly J. , Przepiorka Donna , Nie Lei , Liu Jiang , Sheth Christopher M. , Shapiro Marjorie , Farrell Ann T. , Pazdur Richard
Published: April 2023

Supplemental Table 4 and the accompanying text describe the grouped terms used for the adverse reactions described in Table 2 and the reasons for using grouped terms.
Supplementary Figure S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Authors: Rini Brian I. , Escudier Bernard , Martini Jean-Francois , Magheli Ahmed , Svedman Christer , Lopatin Margarita , Knezevic Dejan , Goddard Audrey D. , Febbo Phillip G. , Li Rachel , Lin Xun , Valota Olga , Staehler Michael , Motzer Robert J. , Ravaud Alain
Published: April 2023

The gene/gene groups and algorithm included in calculating the RS. The RS is derived from the reference-normalized expression measurements, scaled from 0 to 100: Unscaled RS = -0.45 Ã- VN group score -0.31 Ã- IR group score + 0.27 Ã- CGD group score + 0.04 Ã- IL6. RS = 26.4 Ã- (unscaled RS + 3.7). The score is scaled: if RS is <0, then RS=0; and if RS is >100, then RS=100. Abbreviation: RS, recurrence score.
Supplementary Data 1 from Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases
Authors: Chen Fengju , Zhang Yiqun , Gibbons Don L. , Deneen Benjamin , Kwiatkowski David J. , Ittmann Michael , Creighton Chad J.
Published: April 2023

Summary of cancer cases examined in this study, according to data platform. Provided as an Excel file.
Supplementary 5 from Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases
Authors: Chen Fengju , Zhang Yiqun , Gibbons Don L. , Deneen Benjamin , Kwiatkowski David J. , Ittmann Michael , Creighton Chad J.
Published: April 2023

Inter-profile correlations computed between TCGA expression profiles (with values normalized within each cancer type) and profiles from the Fantom consortium expression datasets (both mouse and human), with the correlations averaged across TCGA samples within each pan-cancer class. Provided as an Excel file.
Supplementary Tables from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Authors: Rothé Françoise , Silva Maria Joao , Venet David , Campbell Christine , Bradburry Ian , Rouas Ghizlane , de Azambuja Evandro , Maetens Marion , Fumagalli Debora , Rodrik-Outmezguine Vanessa , Di Cosimo Serena , Rosa Daniela , Chia Stephen , Wardley Andrew , Ueno Takayuki , Janni Wolfgang , Huober Jens , Baselga Jose , Piccart Martine , Loi Sherene , Sotiriou Christos , Dawson Sarah-Jane , Ignatiadis Michail
Published: April 2023

Supplementary Tables
Figure S3 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Authors: Rothé Françoise , Silva Maria Joao , Venet David , Campbell Christine , Bradburry Ian , Rouas Ghizlane , de Azambuja Evandro , Maetens Marion , Fumagalli Debora , Rodrik-Outmezguine Vanessa , Di Cosimo Serena , Rosa Daniela , Chia Stephen , Wardley Andrew , Ueno Takayuki , Janni Wolfgang , Huober Jens , Baselga Jose , Piccart Martine , Loi Sherene , Sotiriou Christos , Dawson Sarah-Jane , Ignatiadis Michail
Published: April 2023

Forest plots for the test of association between changes between baseline and week 2 in ctDNA detection, tested either by taking differences for continuous variables or by taking subgroups of patients who had detectable ctDNA at baseline or not, and (A) pathological complete response (pCR) or (B) event-free survival. All tests are corrected for clinic-pathological characteristics. ctDNA: circulating tumor DNA; VAF: variant allele fraction; OR: odds ratio, HR: hazard ratio; Ci: confidence interval, p: p value.
Figure S4 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Authors: Li Xiaoming , Shepard H. Michael , Cowell Jessica A. , Zhao Chunmei , Osgood Ryan J. , Rosengren Sanna , Blouw Barbara , Garrovillo Sheryl A. , Pagel Mark D. , Whatcott Clifford J. , Han Haiyong , Von Hoff Daniel D. , Taverna Darin M. , LaBarre Michael J. , Maneval Daniel C. , Thompson Curtis B.
Published: April 2023

AsPC-1 parental cells (AsPC-1-P) engineered to overexpress HAS3 (AsPC-1/HAS3, see Materials and Methods) produced more HA in the peritumoral matrix and the stroma.
Table S1 from Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non–Small Cell Lung Cancer
Authors: Yu Hao , Wu Huanmei , Wang Weili , Jolly Shruti , Jin Jian-Yue , Hu Chen , Kong Feng-Ming (Spring)
Published: April 2023

The Scores of CTCAE Pneumonitis and Radiation Pneumonitis
Supplementary Figure S2 from High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling
Authors: Hayashi Takuji , Fujita Kazutoshi , Nojima Satoshi , Hayashi Yujiro , Nakano Kosuke , Ishizuya Yu , Wang Cong , Yamamoto Yoshiyuki , Kinouchi Toshiro , Matsuzaki Kyosuke , Jingushi Kentaro , Kato Taigo , Kawashima Atsunari , Nagahara Akira , Ujike Takeshi , Uemura Motohide , Pena Maria Del Carmen Rodriguez , Gordetsky Jennifer B. , Morii Eiichi , Tsujikawa Kazutake , Netto George J. , Nonomura Norio
Published: April 2023

Body weights, prostate weights, H&E staining and immune cells of CD-fed and HFD-fed mice with or without celecoxib
Supplementary Figure 6 from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Authors: Thompson John A. , Motzer Robert J. , Molina Ana M. , Choueiri Toni K. , Heath Elisabeth I. , Redman Bruce G. , Sangha Randeep S. , Ernst D. Scott , Pili Roberto , Kim Stella K. , Reyno Leonard , Wiseman Aya , Trave Fabio , Anand Banmeet , Morrison Karen , Doñate Fernando , Kollmannsberger Christian K.
Published: April 2023

Supplementary Figure 6. Serum concentration time profiles for AGS-16C3F(CHO) Total Antibody (TAb) (data is presented as Mean {plus minus} SD)
Supplementary Figure 4 from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Authors: Thompson John A. , Motzer Robert J. , Molina Ana M. , Choueiri Toni K. , Heath Elisabeth I. , Redman Bruce G. , Sangha Randeep S. , Ernst D. Scott , Pili Roberto , Kim Stella K. , Reyno Leonard , Wiseman Aya , Trave Fabio , Anand Banmeet , Morrison Karen , Doñate Fernando , Kollmannsberger Christian K.
Published: April 2023

Supplementary Figure 4. Serum concentration time profiles for AGS-16C3F(CHO) free cys-mcMMAF (data is presented as Mean {plus minus} SD)
Supplementary Figure 3 from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Authors: Thompson John A. , Motzer Robert J. , Molina Ana M. , Choueiri Toni K. , Heath Elisabeth I. , Redman Bruce G. , Sangha Randeep S. , Ernst D. Scott , Pili Roberto , Kim Stella K. , Reyno Leonard , Wiseman Aya , Trave Fabio , Anand Banmeet , Morrison Karen , Doñate Fernando , Kollmannsberger Christian K.
Published: April 2023

Supplementary Figure 3. Serum concentration time profiles for AGS-16M8F(Hyb) free cys-mcMMAF (data is presented as Mean {plus minus} SD)
Supplementary Figure 2 from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Authors: Thompson John A. , Motzer Robert J. , Molina Ana M. , Choueiri Toni K. , Heath Elisabeth I. , Redman Bruce G. , Sangha Randeep S. , Ernst D. Scott , Pili Roberto , Kim Stella K. , Reyno Leonard , Wiseman Aya , Trave Fabio , Anand Banmeet , Morrison Karen , Doñate Fernando , Kollmannsberger Christian K.
Published: April 2023

Supplementary Figure 2. Serum concentration time profiles for AGS-16C3F(CHO) antibody drug conjugate (ADC) (data is presented as Mean {plus minus} SD)
Supplementary Method from Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma
Authors: Peng Hao , Dong Di , Fang Meng-Jie , Li Lu , Tang Ling-Long , Chen Lei , Li Wen-Fei , Mao Yan-Ping , Fan Wei , Liu Li-Zhi , Tian Li , Lin Ai-Hua , Sun Ying , Tian Jie , Ma Jun
Published: April 2023

Supplementary Method
Supplementary Figure S5 from Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma
Authors: Cai Zhixiong , Chen Geng , Zeng Yongyi , Dong Xiuqing , Li Zhenli , Huang Yanbing , Xin Fuli , Qiu Liman , Xu Haipo , Zhang Wei , Su Xiaoping , Liu Xiaolong , Liu Jingfeng
Published: April 2023

Figure S5. Kaplan-Meier analysis demonstrating RFS and OS for all enrolled patients stratified by their status of follow up ctDNA.
Supplementary Figure S4 from Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma
Authors: Cai Zhixiong , Chen Geng , Zeng Yongyi , Dong Xiuqing , Li Zhenli , Huang Yanbing , Xin Fuli , Qiu Liman , Xu Haipo , Zhang Wei , Su Xiaoping , Liu Xiaolong , Liu Jingfeng
Published: April 2023

Figure S4.The relationship between SNV fraction, CNV fraction and clinical features. A. The scatter plot showed the Pearson correlation between CNV fraction and SNV fraction. B. The scatter plot showed the Pearson correlation between Tumor size and SNV fraction. C. The scatter plot showed the Pearson correlation between Tumor size and CNV fraction. D. The box plot showed the differences of SNV fraction in patient groups with and without microvascular invasion using students' t test. E. The box plot showed the differences of SNV fraction in patient groups with different level of tumor differentiation using students' t test. F. The box plot showed the differences of SNV fraction in patient groups with or without tumor recurrence using students' t test. G. The box plot showed the differences of CNV fraction in patient groups with and without microvascular invasion using students' t test. H. The box plot showed the differences of CNV fraction in patient groups with different level of tumor differentiation using students' t test. I. The box plot showed the differences of CNV fraction in patient groups with or without tumor recurrence using students' t test.
Supplementary Figure S1 from Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma
Authors: Cai Zhixiong , Chen Geng , Zeng Yongyi , Dong Xiuqing , Li Zhenli , Huang Yanbing , Xin Fuli , Qiu Liman , Xu Haipo , Zhang Wei , Su Xiaoping , Liu Xiaolong , Liu Jingfeng
Published: April 2023

Figure S1. The distribution of known driver genes' somatic SNVs in enrolled patient.
Supplementary Figure S3 from SS18-SSX–Dependent YAP/TAZ Signaling in Synovial Sarcoma
Authors: Isfort Ilka , Cyra Magdalene , Elges Sandra , Kailayangiri Sareetha , Altvater Bianca , Rossig Claudia , Steinestel Konrad , Grünewald Inga , Huss Sebastian , Eßeling Eva , Mikesch Jan-Henrik , Hafner Susanne , Simmet Thomas , Wozniak Agnieszka , Schöffski Patrick , Larsson Olle , Wardelmann Eva , Trautmann Marcel , Hartmann Wolfgang
Published: April 2023

(A) RNAi-mediated reduction of YAP and TAZ protein levels in FUJI cells. To exclude unspecific off-target effects, three siRNAs targeting YAP or TAZ; #1-3 respectively were tested. Knockdown of YAP and TAZ was consistently associated with reduced expression levels of FOXM1 and PLK1 compared to non-targeting negative control siRNA (β-Actin used as loading reference). (B) In HS-SY-II, FUJI and 1273/99 SySa cells expression levels of YAP, TAZ and PLK1 were reduced by treatment with increasing concentrations of verteporfin (β-Actin used as loading reference). (C) In HS-SY-II cells TEAD reporter luciferase activity was significantly decreased upon treatment with verteporfin (***P<0.001). (D) In flow cytometric analyses, increased rates of apoptosis (cleaved PARP) were detected in HS-SY-II cells incubated with verteporfin (**P<0.01).
Supplementary Table T1 from NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells
Authors: Chauvin Cynthia , Joalland Noémie , Perroteau Jeanne , Jarry Ulrich , Lafrance Laura , Willem Catherine , Retière Christelle , Oliver Lisa , Gratas Catherine , Gautreau-Rolland Laetitia , Saulquin Xavier , Vallette François M. , Vié Henri , Scotet Emmanuel , Pecqueur Claire
Published: April 2023

Genomic information of primary GBM cultures
Figure S2 from NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells
Authors: Chauvin Cynthia , Joalland Noémie , Perroteau Jeanne , Jarry Ulrich , Lafrance Laura , Willem Catherine , Retière Christelle , Oliver Lisa , Gratas Catherine , Gautreau-Rolland Laetitia , Saulquin Xavier , Vallette François M. , Vié Henri , Scotet Emmanuel , Pecqueur Claire
Published: April 2023

Expression of VÎ³9VÎ'2 T lymphocyte activation-related molecules in primary GBM cultures.
Figure S1 from NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells
Authors: Chauvin Cynthia , Joalland Noémie , Perroteau Jeanne , Jarry Ulrich , Lafrance Laura , Willem Catherine , Retière Christelle , Oliver Lisa , Gratas Catherine , Gautreau-Rolland Laetitia , Saulquin Xavier , Vallette François M. , Vié Henri , Scotet Emmanuel , Pecqueur Claire
Published: April 2023

Zoledronate induced-reactivity of VÎ³9VÎ'2 T lymphocytes against primary GBM cultures.
Supplementary Figure S4 from Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients
Authors: Laban Simon , Gangkofner Dominik S. , Holzinger Dana , Schroeder Lea , Eichmüller Stefan B. , Zörnig Inka , Jäger Dirk , Wichmann Gunnar , Dietz Andreas , Broglie Martina A. , Herold-Mende Christel C. , Dyckhoff Gerhard , Boscolo-Rizzo Paolo , Ezić Jasmin , Marienfeld Ralf , Möller Peter , Kraus Johann M. , Völkel Gunnar , Kestler Hans A. , Brunner Cornelia , Schuler Patrick J. , Wigand Marlene C. , Theodoraki Marie-Nicole , Doescher Johannes , Hoffmann Thomas K. , Pawlita Michael , Waterboer Tim , Butt Julia
Published: April 2023

Prognostic impact of antibody responses to cancer antigens stratified by HPV-status. Overall survival was significantly shorter for patients with {greater than or equal to}2 AR, AR to c-myc, MAGåE-A1, MAGE-A4 and Rhodopsin E2 in the HPV-negative cohort and IMP-1 in the HPV-positive cohort. Overall survival was calculated using the Kaplan-Meier method and p-values were determined using logrank tests. Results were corrected for multiple testing with a false discovery rate of 15%.
Supplementary Text from L-Carnitine–Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme
Authors: Fink Matthias A. , Paland Heiko , Herzog Susann , Grube Markus , Vogelgesang Silke , Weitmann Kerstin , Bialke Angela , Hoffmann Wolfgang , Rauch Bernhard H. , Schroeder Henry W.S. , Bien-Möller Sandra
Published: April 2023

Additional information on the immunoblot analysis, cell line characteristics and our glioma mouse model
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Authors: Wang Rui , Gao Chan , Raymond Megan , Dito Gennaro , Kabbabe Dominic , Shao Xiao , Hilt Ed , Sun Yongliang , Pak Irene , Gutierrez Martin , Melero Ignacio , Spreafico Anna , Carvajal Richard D. , Ong Michael , Olszanski Anthony J. , Milburn Christina , Thudium Kent , Yang Zheng , Feng Yan , Fracasso Paula M. , Korman Alan J. , Aanur Praveen , Huang Shih-Min A. , Quigley Michael
Published: April 2023

Supplementary Figure 5a
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Authors: Wang Rui , Gao Chan , Raymond Megan , Dito Gennaro , Kabbabe Dominic , Shao Xiao , Hilt Ed , Sun Yongliang , Pak Irene , Gutierrez Martin , Melero Ignacio , Spreafico Anna , Carvajal Richard D. , Ong Michael , Olszanski Anthony J. , Milburn Christina , Thudium Kent , Yang Zheng , Feng Yan , Fracasso Paula M. , Korman Alan J. , Aanur Praveen , Huang Shih-Min A. , Quigley Michael
Published: April 2023

Supplementary Figure 5b
Table 1 from Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome
Authors: Kam Angel Y.F. , Piryani Sadhna O. , McCall Chad M. , Park Hee Su , Rizzieri David A. , Doan Phuong L.
Published: April 2023

Patient Demographics
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Authors: Wang Rui , Gao Chan , Raymond Megan , Dito Gennaro , Kabbabe Dominic , Shao Xiao , Hilt Ed , Sun Yongliang , Pak Irene , Gutierrez Martin , Melero Ignacio , Spreafico Anna , Carvajal Richard D. , Ong Michael , Olszanski Anthony J. , Milburn Christina , Thudium Kent , Yang Zheng , Feng Yan , Fracasso Paula M. , Korman Alan J. , Aanur Praveen , Huang Shih-Min A. , Quigley Michael
Published: April 2023

Supplementary Figure 6
Supplementary Data from Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome
Authors: Kam Angel Y.F. , Piryani Sadhna O. , McCall Chad M. , Park Hee Su , Rizzieri David A. , Doan Phuong L.
Published: April 2023

Figs S1-S7
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Authors: Wang Rui , Gao Chan , Raymond Megan , Dito Gennaro , Kabbabe Dominic , Shao Xiao , Hilt Ed , Sun Yongliang , Pak Irene , Gutierrez Martin , Melero Ignacio , Spreafico Anna , Carvajal Richard D. , Ong Michael , Olszanski Anthony J. , Milburn Christina , Thudium Kent , Yang Zheng , Feng Yan , Fracasso Paula M. , Korman Alan J. , Aanur Praveen , Huang Shih-Min A. , Quigley Michael
Published: April 2023

Supplementary Figure 8
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Authors: Wang Rui , Gao Chan , Raymond Megan , Dito Gennaro , Kabbabe Dominic , Shao Xiao , Hilt Ed , Sun Yongliang , Pak Irene , Gutierrez Martin , Melero Ignacio , Spreafico Anna , Carvajal Richard D. , Ong Michael , Olszanski Anthony J. , Milburn Christina , Thudium Kent , Yang Zheng , Feng Yan , Fracasso Paula M. , Korman Alan J. , Aanur Praveen , Huang Shih-Min A. , Quigley Michael
Published: April 2023

Supplementary Figure 9
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Authors: Wang Rui , Gao Chan , Raymond Megan , Dito Gennaro , Kabbabe Dominic , Shao Xiao , Hilt Ed , Sun Yongliang , Pak Irene , Gutierrez Martin , Melero Ignacio , Spreafico Anna , Carvajal Richard D. , Ong Michael , Olszanski Anthony J. , Milburn Christina , Thudium Kent , Yang Zheng , Feng Yan , Fracasso Paula M. , Korman Alan J. , Aanur Praveen , Huang Shih-Min A. , Quigley Michael
Published: April 2023

Supplementary Figure 10
Table S1 from A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
Authors: Iizuka Akira , Nonomura Chizu , Ashizawa Tadashi , Kondou Ryota , Ohshima Keiichi , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Akiyama Yasuto
Published: April 2023

Flow cytometry analysis of spleen cells from control or anti-B7H4/CD3 bispecific antibody-treated mice bearing MDA-MB-468 tumors
Supplementary Data from Ligand-binding Domain–activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells
Authors: Zinger Lotem , Merenbakh-Lamin Keren , Klein Anat , Elazar Adi , Journo Shani , Boldes Tomer , Pasmanik-Chor Metsada , Spitzer Avishay , Rubinek Tami , Wolf Ido
Published: April 2023

S1: LBD-ER mutations are expressed at physiologic levels and are E2-independent. S2: LBD-ER lead to an enrichment pathway of ECM degradation S3: High concentrations of E2 do not recapitulate the mutant phenotype in WT-ER expressing cells. S4: LBD-mutations activate the AKT/mTOR pathway. S5: Mitochondrial activity of D538G-ER expressing T47D cells. S6: Glutamine leads to enrichment of specific pathways by 537S-ER.
Table S3 from First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Authors: Tao Jessica J. , Cangemi Nicholas A. , Makker Vicky , Cadoo Karen A. , Liu Joyce F. , Rasco Drew W. , Navarro Willis H. , Haqq Christopher M. , Hyman David M.
Published: April 2023

Baseline, end of treatment, and change in ECOG performance status from baseline to end of treatment is reported below. Abbreviations: ECOG, Eastern Cooperative Oncology Group.
Table S2 from First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Authors: Tao Jessica J. , Cangemi Nicholas A. , Makker Vicky , Cadoo Karen A. , Liu Joyce F. , Rasco Drew W. , Navarro Willis H. , Haqq Christopher M. , Hyman David M.
Published: April 2023

Change and end of treatment values for albumin, hemoglobin, and absolute lymphocytes among the 32 patients are summarized below. Abbreviations: SD, stable disease.
Supplementary Data from Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
Authors: Yeung Tsz-Lun , Leung Cecilia S. , Yip Kay-Pong , Sheng Jianting , Vien Long , Bover Laura C. , Birrer Michael J. , Wong Stephen T.C. , Mok Samuel C.
Published: April 2023

Supplementary figures and methods
Supplementary Tables from Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas
Authors: Zhao Shuang G. , Chen William S. , Das Rajdeep , Chang S. Laura , Tomlins Scott A. , Chou Jonathan , Quigley David A. , Dang Ha X. , Barnard Travis J. , Mahal Brandon A. , Gibb Ewan A. , Liu Yang , Davicioni Elai , Duska Linda R. , Posadas Edwin M. , Jolly Shruti , Spratt Daniel E. , Nguyen Paul L. , Maher Christopher A. , Small Eric J. , Feng Felix Y.
Published: April 2023

Supplemental Tables 1-7
Supplementary Table S3 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S3
Supplementary Table S11 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S11
Supplementary Table S10 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S10
Supplementary Table 3 from Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy
Authors: de Roest Reinout H. , Mes Steven W. , Poell Jos B. , Brink Arjen , van de Wiel Mark A. , Bloemena Elisabeth , Thai Elena , Poli Tito , Leemans C. René , Brakenhoff Ruud H.
Published: April 2023

Table with detailed follow-up data of the complete CRT treated patient cohort.
Suppl. Fig. 6 from Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment
Authors: Luo Ren , Firat Elke , Gaedicke Simone , Guffart Elena , Watanabe Tsubasa , Niedermann Gabriele
Published: April 2023

Induction of CXCL10 expression in tumor cells by cisplatin or IFN-gamma.
Suppl. Fig. 4 from Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment
Authors: Luo Ren , Firat Elke , Gaedicke Simone , Guffart Elena , Watanabe Tsubasa , Niedermann Gabriele
Published: April 2023

Ratio of tumor-specific CD8+ T cells to tumor cells is enhanced upon treatment with cisplatin + anti-PD-1.
Table S9 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Effects of APOBEC3 and UNG polymorphisms on the generation of AOPBEC-signature HBV mutation
Table S8 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Associations of UNG polymorphisms with the risk of HCC in subjects with/without APOBEC3B deletion
Supplementary Figure 4 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 4
Table S2 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Primers for the genotyping of APOBEC3 and UNG genetic polymorphisms, PCR, and quantitative RT-PCR
Table S12 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Demographic characteristics of hepatocellular carcinoma patients in LIHC and GSE14520 cohort
Table S10 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Multivariate Cox regression analysis for the disease specific survival of patients with HCC
List of Supplementary Data from Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
Authors: Jonsson Philip , Lin Andrew L. , Young Robert J. , DiStefano Natalie M. , Hyman David M. , Li Bob T. , Berger Michael F. , Zehir Ahmet , Ladanyi Marc , Solit David B. , Arnold Angela G. , Stadler Zsofia K. , Mandelker Diana , Goldberg Michael E. , Chmielecki Juliann , Pourmaleki Maryam , Ogilvie Shahiba Q. , Chavan Shweta S. , McKeown Andrew T. , Manne Malbora , Hyde Allison , Beal Kathryn , Yang T. Jonathan , Nolan Craig P. , Pentsova Elena , Omuro Antonio , Gavrilovic Igor T. , Kaley Thomas J. , Diamond Eli L. , Stone Jacqueline B. , Grommes Christian , Boire Adrienne , Daras Mariza , Piotrowski Anna F. , Miller Alexandra M. , Gutin Philip H. , Chan Timothy A. , Tabar Viviane S. , Brennan Cameron W. , Rosenblum Marc , DeAngelis Lisa M. , Mellinghoff Ingo K. , Taylor Barry S.
Published: April 2023

List of Supplementary Data
Supplementary Table S1 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
Authors: Lazzari Luca , Corti Giorgio , Picco Gabriele , Isella Claudio , Montone Monica , Arcella Pamela , Durinikova Erika , Zanella Eugenia R. , Novara Luca , Barbosa Fabiane , Cassingena Andrea , Cancelliere Carlotta , Medico Enzo , Sartore-Bianchi Andrea , Siena Salvatore , Garnett Mathew J. , Bertotti Andrea , Trusolino Livio , Di Nicolantonio Federica , Linnebacher Michael , Bardelli Alberto , Arena Sabrina
Published: April 2023

Supplementary Table S1
Supplementary Figure S3 from Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
Authors: Current Kyle , Meyer Catherine , Magyar Clara E. , Mona Christine E. , Almajano Joel , Slavik Roger , Stuparu Andreea D. , Cheng Chloe , Dawson David W. , Radu Caius G. , Czernin Johannes , Lueckerath Katharina
Published: April 2023

PSMA expression is heterogenous in human PC
Figure S1 from Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Authors: Prabhu Varun V. , Madhukar Neel S. , Gilvary Coryandar , Kline C. Leah B. , Oster Sophie , El-Deiry Wafik S. , Elemento Olivier , Doherty Faye , VanEngelenburg Alexander , Durrant Jessica , Tarapore Rohinton S. , Deacon Sean , Charter Neil , Jung Jinkyu , Park Deric M. , Gilbert Mark R. , Rusert Jessica , Wechsler-Reya Robert , Arrillaga-Romany Isabel , Batchelor Tracy T. , Wen Patrick Y. , Oster Wolfgang , Allen Joshua E.
Published: April 2023

Figure S1
Supplemental Table 1 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Lee Oukseub , Sullivan Megan E. , Xu Yanfei , Rogers Chiara , Muzzio Miguel , Helenowski Irene , Shidfar Ali , Zeng Zexian , Singhal Hari , Jovanovic Borko , Hansen Nora , Bethke Kevin P. , Gann Peter H. , Gradishar William , Kim J. Julie , Clare Susan E. , Khan Seema A.
Published: April 2023

Supplemental table 1. Differential gene expression and pathway enrichment analysis in TPA responders (excel file) -uploading separately.
Supplementary Table S7 from Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling
Authors: Ji Jianxiong , Xu Ran , Ding Kaikai , Bao Guoqing , Zhang Xin , Huang Bin , Wang Xinyu , Martinez Aurora , Wang Xiuying , Li Gang , Miletic Hrvoje , Thorsen Frits , Bjerkvig Rolf , Xiang Lei , Han Bo , Chen Anjing , Li Xingang , Wang Jian
Published: April 2023

Most significant decreasing protein partners of HNRNPL after SChLAP1 knockdown
Supplementary Table S5 from Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling
Authors: Ji Jianxiong , Xu Ran , Ding Kaikai , Bao Guoqing , Zhang Xin , Huang Bin , Wang Xinyu , Martinez Aurora , Wang Xiuying , Li Gang , Miletic Hrvoje , Thorsen Frits , Bjerkvig Rolf , Xiang Lei , Han Bo , Chen Anjing , Li Xingang , Wang Jian
Published: April 2023

Association between SChLAP1 expression and clinicopathological factors in glioma
Figure S1 from Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Authors: Yu Jiayi , Yan Junya , Guo Qian , Chi Zhihong , Tang Bixia , Zheng Bin , Yu Jinyu , Yin Ting , Cheng Zhiyuan , Wu Xiaowen , Yu Huan , Dai Jie , Sheng Xinan , Si Lu , Cui Chuanliang , Bai Xue , Mao Lili , Lian Bin , Wang Xuan , Yan Xieqia , Li Siming , Zhou Li , Flaherty Keith T. , Guo Jun , Kong Yan
Published: April 2023

Supplementary Figure S1. The flow chart describing the total population of the study.
Supplementary Figure 8 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Authors: Montanuy Helena , Martínez-Barriocanal Águeda , Antonio Casado José , Rovirosa Llorenç , Ramírez Maria José , Nieto Rocío , Carrascoso-Rubio Carlos , Riera Pau , González Alan , Lerma Enrique , Lasa Adriana , Carreras-Puigvert Jordi , Helleday Thomas , Bueren Juan A. , Arango Diego , Minguillón Jordi , Surrallés Jordi
Published: April 2023

Figure S8. Additional data on genotoxicity in blood samples from WT or Fanca-deficient mice, by gefitinib and afatinib treatment.
Supplementary Figure 4 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Authors: Montanuy Helena , Martínez-Barriocanal Águeda , Antonio Casado José , Rovirosa Llorenç , Ramírez Maria José , Nieto Rocío , Carrascoso-Rubio Carlos , Riera Pau , González Alan , Lerma Enrique , Lasa Adriana , Carreras-Puigvert Jordi , Helleday Thomas , Bueren Juan A. , Arango Diego , Minguillón Jordi , Surrallés Jordi
Published: April 2023

Figure S4. Additional data on toxicity experiments in Fanca-deficient mice.
Supplementary Figure 3 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Authors: Montanuy Helena , Martínez-Barriocanal Águeda , Antonio Casado José , Rovirosa Llorenç , Ramírez Maria José , Nieto Rocío , Carrascoso-Rubio Carlos , Riera Pau , González Alan , Lerma Enrique , Lasa Adriana , Carreras-Puigvert Jordi , Helleday Thomas , Bueren Juan A. , Arango Diego , Minguillón Jordi , Surrallés Jordi
Published: April 2023

Figure S3. Additional immunohistochemistry images from tumor xenografts.
Table S2 from Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study
Authors: Qiao Guoliang , Wang Xiaoli , Zhou Lei , Zhou Xinna , Song Yuguang , Wang Shuo , Zhao Lei , Morse Michael A. , Hobeika Amy , Song Jin , Yi Xin , Xia Xuefeng , Ren Jun , Lyerly Herbert Kim
Published: April 2023

Supplementary table 2: Somatic SNVs and InDels in plasma samples by analyzing the sequencing data(N=30).
Table S1 from Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study
Authors: Qiao Guoliang , Wang Xiaoli , Zhou Lei , Zhou Xinna , Song Yuguang , Wang Shuo , Zhao Lei , Morse Michael A. , Hobeika Amy , Song Jin , Yi Xin , Xia Xuefeng , Ren Jun , Lyerly Herbert Kim
Published: April 2023

Supplementary table 1: Cox proportional hazard regression analysis of patients' demographic and clinical characteristics related with overall survival.
Supplementary Table 9 from Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer
Authors: Huang Lei , David Odile , Cabay Robert J. , Valyi-Nagy Klara , Macias Virgilia , Zhong Rong , Wenig Barry , Feldman Lawrence , Weichselbaum Ralph , Spiotto Michael T.
Published: April 2023

Supplemental Table 9. Breast cancer characteristics
Figure S4 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Authors: Yan Zi-Xun , Li Li , Wang Wen , OuYang Bin-Shen , Cheng Shu , Wang Li , Wu Wen , Xu Peng-Peng , Muftuoglu Muharrem , Hao Ming , Yang Su , Zhang Mu-Chen , Zheng Zhong , Li James , Zhao Wei-Li
Published: April 2023

Supplementary Figure S4. EGFR+ and Ki67+ expression in the complete remission and partial remission patients after CAR T treatment. Immunohistochemistry of CAR T cells (EGFR+, red) and Ki67+ (brown) in tumor samples of the complete remission (CR) and partial remission (PR) patients after CAR T treatment. The cells were counted from five randomly selected visions. Bar plots showing the comparison of absolute quantification of double EGFR+Ki67+ cells.